Eyenovia

Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia

Retrieved on: 
Tuesday, June 30, 2020

We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.

Key Points: 
  • We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.
  • The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age.
  • The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovias proprietary atropine topical micro-formulation delivered by the Optejet dispenser.
  • MicroPine (atropine ophthalmic solution) is Eyenovia's first-in-class topical treatment for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness.

Eyenovia to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 4, 2020

NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that members of management will be participating in two upcoming investor conferences.

Key Points: 
  • NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that members of management will be participating in two upcoming investor conferences.
  • Eyenovias pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.
  • Eyenovia believes that its administration of pilocarpine using the companys high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability.
  • Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.

Eyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline

Retrieved on: 
Tuesday, October 29, 2019

In addition, a telephonic replay of the call will be available until November 5, 2019.

Key Points: 
  • In addition, a telephonic replay of the call will be available until November 5, 2019.
  • The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404-537-3406 (International) with confirmation code 3192808.
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology.
  • Eyenovias pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.

Eyenovia to Participate in Multiple Upcoming Medical Meetings

Retrieved on: 
Wednesday, October 2, 2019

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it will be presenting at multiple eyecare meetings in October.

Key Points: 
  • NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it will be presenting at multiple eyecare meetings in October.
  • Experts in optometry and ophthalmology as well as Eyenovias management team plans to highlight the Companys late stage clinical pipeline, data from its MicroStat Phase III MIST-1 and MIST-2 studies for pharmacologic mydriasis, as well as new usability data generated from its MicroPine Phase III study in pediatric progressive myopia.
  • Eyenovias pipeline is currently focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma and other eye diseases.
  • For more information please visit www.eyenovia.com .

Eyenovia to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 3, 2019

The webcast will be archived for 90 days following the live presentation on the Company's website.

Key Points: 
  • The webcast will be archived for 90 days following the live presentation on the Company's website.
  • Eyenovias management team will also be available for one-on-one meetings with investors who are registered to attend the events.
  • Alternatively, interested investors may contact Tram Bui of The Ruth Group at [email protected] or (646) 536-7035 to schedule a meeting.
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patent piezo-print delivery technology.